Compare Ginkgo Bioworks Holdings Inc (DNA) vs Freeport-McMoRan Inc (FCX) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.21, down 3.99% on the day, reflecting a bearish technical trend. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous labs and contract research. Despite beating EPS estimates in two of the last three quarters, it remains deeply unprofitable with a net income margin of -219.6% in 2025. Analyst sentiment is mixed with a 45% buy rating, but institutional selling and negative cash flows highlight significant challenges.

The outlook is cautious. While the pivot to new business lines offers long-term potential, near-term execution risks and persistent losses pose substantial downside. Investors face high volatility amid uncertain revenue growth and cash burn, requiring careful risk assessment against any speculative recovery thesis.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.